Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6249724 | 0.86 | LMNA (0.65) | KDM4ETSHRLMNAHTTHSD17B10 | |
| SCHEMBL6247006 | 0.81 | KDM4E (1.00) | KDM4ETSHRLMNAHSD17B10ALDH1A1 | |
| SCHEMBL4209449 | 0.80 | TSHR (1.00) | KDM4ETSHRLMNAHTTHSD17B10 | |
| SCHEMBL17298058 | 0.79 | KDM4E (0.69) | KDM4ETSHRLMNAHTTHSD17B10 | |
| SCHEMBL4206412 | 0.79 | TSHR (0.83) | KDM4ETSHRLMNAHTTHSD17B10 | |
| SCHEMBL22019391 | 0.78 | ALDH1A1 (0.74) | KDM4ETSHRLMNAHTTHSD17B10 | |
| SCHEMBL1544901 | 0.78 | LMNA (0.55) | KDM4ETSHRLMNAHTTHSD17B10 | |
| SCHEMBL22019403 | 0.77 | ALDH1A1 (0.60) | KDM4ETSHRLMNAHTTHSD17B10 | |
| SCHEMBL4212106 | 0.77 | TSHR (0.76) | TSHRLMNAHTTHSD17B10ALDH1A1 | |
| SCHEMBL4213467 | 0.77 | TSHR (0.80) | TSHRLMNAHTTHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311830-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-1723144-B1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-7585881-B2 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080015204-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015234-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20070293545-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-20070179188-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | US | disclosed |
| EP-1723144-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006014185-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-02-09 | — | — | WO | disclosed |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
| WO-2005044008-A2 | 2 -AMINOTHIOPHENE COMPOUNDS AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-05-19 | — | — | WO | disclosed |
| EP-1529045-A2 | NEW COMPOUNDS | Astra Zeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040152699-A1 | Compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004014881-A2 | '1,2,4'OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRA ZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152699-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | KDM4E 3749/4885TSHR 4088/4885LMNA 900/4885 |
| US-20080015234-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | KDM4E 3036/4885TSHR 895/4885LMNA 4509/4885 |
| US-20070179188-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | KDM4E 2969/4885TSHR 847/4885LMNA 4539/4885 |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | KDM4E 3036/4885TSHR 895/4885LMNA 4509/4885 |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | KDM4E 3036/4885TSHR 895/4885LMNA 4509/4885 |
| US-20070293545-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | KDM4E 3036/4885TSHR 895/4885LMNA 4509/4885 |
| US-20080015204-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | KDM4E 3036/4885TSHR 895/4885LMNA 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.